Main Menu
Main Menu
The news items below include announcements from companies in the Brain Tumor Investment Fund™ portfolio. These announcements are produced by the companies themselves. Their content, including any forward-looking or investigational claims, is the responsibility of the issuing company. Brain Tumor Investment Fund™ and National Brain Tumor Society do not specifically endorse or verify third-party statements, and investigational therapies referenced have not been proven safe or effective and are not approved by the U.S. Food and Drug Administration.
Portfolio Spotlight: Alpheus Medical One of the things we look for in a BTIF portfolio company is a genuinely novel approach to treating brain tumors. Alpheus Medical is one of those companies. A Different Kind of Treatment Alpheus is developing a type of drug-led therapy it calls “Porphyrin Metabolite Activation” or, simply “PoMA.” The approach builds on the FDA-approved […] June 3, 2026
Trogenix doses first patient in Phase I/II glioblastoma gene therapy trial Trogenix, a Brain Tumor Investment Fund™ portfolio company, has announced that the first patient has been dosed in ADePT, a phase I/II clinical trial of its investigational gene therapy TGX-007 for newly diagnosed and recurrent glioblastoma (GBM). The trial is now open at two sites: NHS Lothian in the United Kingdom and Ohio State University […] June 2, 2026
FOX 26 Houston: Diakonos’s Experimental Immunotherapy for Glioblastoma Shows Promising Survival Gains in Early Trials FOX 26 Houston reports on early clinical data from BTIF portfolio company Diakonos Oncology’s investigational dendritic cell immunotherapy for glioblastoma. The report highlights phase I trial results and features a patient currently receiving the treatment. Diakonos’s vaccine therapy — known as Dubodencel or DOC1021 — uses a patient’s own tumor DNA to prime dendritic cells, […] April 16, 2026
Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment. CHANHASSEN, MN, April 9, 2026 – Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date […] April 14, 2026
Trogenix Publishes Glioblastoma Gene Therapy Research in Nature Trogenix Ltd., a Brain Tumor Investment Fund™ (BTIF) portfolio company, has published new preclinical research on its synthetic super-enhancer gene therapy platform for glioblastoma in the journal Nature. The paper describes the technology behind Trogenix’s lead program, which the company plans to advance into a first-in-human clinical trial later this year. The full paper is available […] April 13, 2026